CIK 0001649989
- Non-accelerated filer
- Smaller reporting company
Outlook Therapeutics, Inc.
Sign in to watch- Ticker
- OTLK
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Sep 30
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 383982704
- Phone
- +1 609-619-3990
- Business address
- 111 S. WOOD AVENUE, UNIT #100, ISELIN, NJ, 08830
- Former names
- Oncobiologics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 71 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-04-21 | BioLexis Pte Ltd. 10% owner | Other disposition | −27,982,529 | 22,982,529 | ||
| 2020-03-23 | BioLexis Pte Ltd. Director | Exercise or conversion | +29,358,621 | 50,965,058 | ||
| 2020-03-23 | BioLexis Pte Ltd. Director | Exercise or conversion · Series A-1 Convertible Preferred Stock | −68,112 | 0 | ||
| 2020-03-19 | BioLexis Pte Ltd. Director | Returned to the company · Series A-1 Convertible Preferred Stock | −68,112 | 0 | ||
| 2020-03-19 | BioLexis Pte Ltd. Director | Grant or award · Series A-1 Convertible Preferred Stock | +68,112 | 68,112 | ||
| 2020-01-29 | BioLexis Pte Ltd. Director | Exercise or conversion | +4,657,852 | $0.23 | $1.1M | 21,606,437 |
| 2020-01-29 | BioLexis Pte Ltd. Director | Exercise or conversion · Warrant (Right to Buy) | −2,093,750 | 0 | ||
| 2020-01-29 | BioLexis Pte Ltd. Director | Exercise or conversion · Warrant (Right to Buy) | −1,282,051 | $1.00 | $1.3M | 0 |
| 2020-01-29 | BioLexis Pte Ltd. Director | Exercise or conversion · Warrant (Right to Buy) | −1,282,051 | $1.00 | $1.3M | 0 |
| 2020-01-27 | BioLexis Pte Ltd. Director | Returned to the company · Warrant (Right to Buy) | −2,093,750 | 0 | ||
| 2020-01-27 | BioLexis Pte Ltd. Director | Grant or award · Warrant (Right to Buy) | +2,093,750 | 2,039,750 | ||
| 2020-01-27 | BioLexis Pte Ltd. Director | Returned to the company · Warrant (Right to Buy) | −1,282,051 | $1.00 | $1.3M | 0 |
| 2020-01-27 | BioLexis Pte Ltd. Director | Grant or award · Warrant (Right to Buy) | +1,282,051 | $1.00 | $1.3M | 1,282,051 |
| 2020-01-27 | BioLexis Pte Ltd. Director | Returned to the company · Warrant (Right to Buy) | −1,282,051 | $1.00 | $1.3M | 0 |
| 2020-01-27 | BioLexis Pte Ltd. Director | Grant or award · Warrant (Right to Buy) | +1,282,051 | $1.00 | $1.3M | 1,282,051 |
| 2019-12-31 | BioLexis Pte Ltd. Director | Other acquisition · Series A-1 Convertible Preferred Stock | +1,661 | 68,112 | ||
| 2019-12-23 | BioLexis Pte Ltd. Director | Exercise or conversion | +2,909,091 | $0.23 | $675K | 16,948,585 |
| 2019-12-23 | BioLexis Pte Ltd. Director | Exercise or conversion · Warrant (Right to Buy) | −3,636,364 | 0 | ||
| 2019-09-30 | BioLexis Pte Ltd. Director | Other acquisition · Series A-1 Convertible Preferred Stock | +1,620 | 66,451 | ||
| 2019-06-30 | BioLexis Pte Ltd. Director | Other acquisition · Series A-1 Convertible Preferred Stock | +1,581 | 64,831 |
Page 1 of 2 · 27 trades